A Phase II Study of AS1411 in Renal Cell Carcinoma

Antisoma Research

Status and phase: Unknown; Phase 2

Conditions: Metastatic Renal Cell Carcinoma

Treatments: Drug: AS1411

Study type: Interventional

Funder types: Industry

Identifiers

NCT00740441

AS1411-C-202

Details and patient eligibility

About

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology
• Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)

Exclusion criteria

• Collecting duct histology
• A history of bleeding disorders or currently taking oral vitamin K antagonise medication
• Unstable brain metastases
• History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

A

Experimental group

Description:

AS1411 treatment

Treatment:

Drug: AS1411